Dr. Stephanie Greenham is a clinical psychologist, the Clinical Team Lead for Inpatient Mental Health, and the Professional Practice Leader/Coordinator for Psychology at CHEO. She earned her PhD in Clinical Psychology in 1999 from the University of Ottawa and has been at CHEO since that time. Throughout her 20 years at CHEO, Stephanie has been involved in the development, implementation, and oversight of outcomes management approaches to inpatient and day treatment mental health services for children and youth. As a Clinical Investigator with the CHEO Research Institute, she received funding to study the outcomes of acute inpatient psychiatric care.
Her research interests include predictors of psychiatric re-admission; pathways to suicide risk; sleep disruption and depression; and outcomes management. Stephanie is a Clinical Professor at the University of Ottawa in the School of Psychology and an Adjunct Professor at Carleton University in the Department of Psychology. She is a founding member of and continues to be actively involved in both provincial and national networks supporting child and adolescent inpatient psychiatry services (ONCAIPS and CCAPINet), which has included the development of standards of inpatient psychiatric care.
Development of a Clinical Pathway for the Assessment and Management of Suicidality on a Pediatric Psychiatric Unit
This framework, developed with the aim to standardize care for psychiatrically admitted suicidal children and adolescents, may serve as a flexible template for use in similar settings and could be adapted according to local realities and resources.
Medications for sleep disturbance in children and adolescents with depression: a survey of Canadian child and adolescent psychiatrists
Melatonin and certain off-label psychotropic drugs are perceived as being more effective and appropriate to address sleep disturbances in children and adolescents with depression.
Could long-term administration of melatonin to prepubertal children affect timing of puberty? A clinician’s perspective
We conclude that to investigate an association between melatonin and pubertal timing, it will be important to conduct long-term randomized controlled trials of latency age children and also examine the cellular and systems-level interactions between melatonin and kisspeptin, a recently identified neuropeptide with a locus of action at the gonadotropin releasing hormone neurons that is important in contributing to the timing of puberty onset.